|Assessment Status||Assessment process complete|
|Indication||For the prevention of vaso-occlusive complications of sickle cell disease in patients over two years of age.|
|Rapid review commissioned||20/04/2020|
|Rapid review completed||14/05/2020|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that hydroxycarbamide (Xromi®) not be considered for reimbursement at the submitted price.*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement; August 2020.